Bryce Point Capital’s Keros Therapeutics KROS Stock Holding History

Bryce Point Capital’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-28,127	Closed	-$445K	–	329
2024 Q4	$445K	Buy	+28,127	New	+$1.46M	0.13%	368

Other funds holding KROS

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bryce Point Capital's KROS Position: Q1 2025 in Review

Bryce Point Capital sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 28,127 shares — an estimated $445K sold.

Bryce Point Capital first reported a position in KROS in Q4 2024 and held it in 1 quarter. The position peaked at $445K in Q4 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

Bryce Point Capital reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
Bryce Point Capital sold 28,127 Keros Therapeutics shares in Q1 2025, an estimated $445K.
Bryce Point Capital first reported a position in Keros Therapeutics in Q4 2024 and held it in 1 quarter.
Bryce Point Capital's Keros Therapeutics position peaked at $445K in Q4 2024.
156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Bryce Point Capital's 13F filing for Q1 2025, filed 7 May 2025.